EschbachJ.W., HaleyN.R., AdamsonJ.W.. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.Contrib Nephrol1990; 78: 24–36.
2.
MacGregorM.S., RoweP.A., WatsonM.A., RodgerR.S., JunorB.J., BriggsJ.D.. Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors.Nephron1996; 74: 517–21.
3.
GossmannJ., ThurmannP., BachmannT.. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients.Kidney Int1996; 50: 973–8.
4.
UsalanC., ErdemY., CaglarM.. Effect of enalapril on exaggerated erythropoietin response to phlebotomy in erythrocytosic renal transplant patients.Nephrol Dial Transplant1998; 13: 2884–9.
5.
KuriyamaR., KogureH., ItohS.. Angiotensin converting enzyme inhibitor induced anemia in a kidney transplant recipient.Transplant Proc1996; 28: 1635.
6.
HirakataH., OnoyamaK., HoriK., FujishimaM.. Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients.Clin Nephrol1986; 26: 27–32.
7.
SizelandP.C., BaileyR.R., LynnK.L., RobsonR.A.. Anemia and angiotensin-converting enzyme inhibition in renal transplant recipients.J Cardiovasc Pharmacol1990; 16(suppl. 7): S117–9.
8.
OnoyamaK., SanaiT., MotomuraK., FujishimaM.. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients.J Cardiovasc Pharmacol1989; 13(suppl.): S27–30.
9.
SchifflH., LangS.M.. Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease.Nephron1999; 81: 106–8.
DhontA.W., VanholderR.C., RingoirS.M.. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients.Nephrol Dial Transplant1995; 10: 2107–9.
15.
AlbitarS., GeninR., FenC.M., ServeauxM.O., BourgeonB.. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.Nephrol Dial Transplant1998; 13: 1206–10.
16.
CharytanC., Goldfarb-RumyantzevA., WangY.F., SchwenkM.H., SpinowitzB.S.. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.Am J Nephrol1998; 18: 498–503.
17.
NavarroJ.F., MaciaM.L., MoraF.C.. Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients.Adv Perit Dial1997; 13: 257–9.
18.
AkpolatT., GumusT., BedirA., AdamB.. Acute effect of trandolapril on serum erythropoietin in uremic and hypertensive patients.J Nephrol1998; 11: 94–7.
19.
AltunB., AriciM., YasavulU., TurganC., CaglarS.. Role of erythropoietin in pathogenesis of post transplant erythrocytosis (PTE) and mechanism of losartan's efficiency.Nephrol Dial Transplant1997; 12: 626–7.
20.
JulianB.A., Brantley-RRJ, BarkerC.V.. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.J Am Soc Nephrol1998; 6: 1104–8.
21.
DuclouxD., FournierV., BressonV.C., ChalopinJ.M.. Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis.Transplant Int1998; 11: 312–5.
22.
KlaassenR.J., vanG.T., RischenV.J., DeinumJ., ManI., WeimarW.. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with post-transplant erythrocytosis.Transplantation1997; 64: 780–2.
23.
ShandB.I., GilchristN.L., NichollsM.G., BaileyR.R.. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study.J Hum Hypertens1995; 9: 233–5.
24.
WeberM.. Clinical safety and tolerability of losartan.Clin Ther1997; 19: 604–16.
25.
BelcherG., HubnerR., GeorgeM., ElmfeldtD., LundeH.. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension.J Hum Hypertens1997; 11(suppl. 2): S85–9.
26.
SarachoR., MartinM.A., MartinezI., AljamaP., MontenegroJ.. Evaluation of the losartan in hemodialysis (ELHE) study.Kidney Int1998; 54(suppl.): S125–9.
27.
LangS.M., SchifflH.. Losartan and anaemia of end-stage renal disease.Lancet1998; 352: 1708.
28.
SchwarzbeckA., WttenmeierK.W., HallfritzschU.. Anaemia in dialysis patients as a side-effect of sartanes.Lancet1998; 352: 286.
29.
PlumJ., BuntenB., NemethR., GrabenseeB.. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.J Am Soc Nephrol1998; 9: 2223–4.
EsmailZ.N., LoewenP.S.. Losartan as an alternative to ACE inhibitors in patients with renal dysfunction.Ann Pharmacother1998; 32: 1096–8.
32.
MarkhamA., GoaK.L.. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.Drugs1997; 54: 299–311.
33.
Castillo delD., CampistolJ.M., GuiradoL.. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients.Kidney Int1998; 68(suppl.): S135–9.
34.
MatsumuraM., NomuraH., KoniI., MabuchiH.. Angiotensinconverting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Risks of Cardiac Disease in Dialysis Patients Study Group.Nephron1997; 77: 164–8.
35.
PrattM.C., LewisB.N., WalkerR.J., BaileyR.R., ShandB.I., LiveseyJ.. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers.Br J Clin Pharmacol1992; 34: 363–5.
36.
MrugM., StopkaT., JulianB.A., PrchalJ.F., PrchalJ.T.. Angiotensin II stimulates proliferation of normal early erythroid progenitors.J Clin Invest1997; 100: 2310–4.
37.
AziziM., RousseauA., EzanE.. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.J Clin Invest1996; 97: 839–44.
38.
MorroneL.F., DiP.S., LogolusoF.. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines.Transplantation1997; 64: 913–8.
39.
ErturkS., NergizogluG., AtesK.. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients.Nephrol Dial Transplant1999; 14(8): 1912–6.
40.
ChewC.G., WeiseM.D., DisneyA.P.. The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients.Nephrol Dial Transplant1999; 14(8): 2047–9.
41.
MacdougallI.C.. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin.Nephrol Dial Transplant1999; 14(8): 1836–41.
